Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
1998 1
1999 1
2008 1
2012 1
2017 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Kaposi Sarcoma NCI Grade 3"
Page 1
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.
Rajdev L, Jackie Wang CC, Joshi H, Lensing S, Lee J, Ramos JC, Baiocchi R, Ratner L, Rubinstein PG, Ambinder R, Henry D, Streicher H, Little RF, Chiao E, Dittmer DP, Einstein MH, Cesarman E, Mitsuyasu R, Sparano JA; AIDS Malignancy Consortium. Rajdev L, et al. Cancer. 2024 Mar 15;130(6):985-994. doi: 10.1002/cncr.35110. Epub 2023 Nov 14. Cancer. 2024. PMID: 37962072
BACKGROUND: Although immunotherapy has emerged as a therapeutic strategy for many cancers, there are limited studies establishing the safety and efficacy in people living with HIV (PLWH) and cancer. METHODS: PLWH and solid tumors or Kaposi sarcoma (KS) receiving ant …
BACKGROUND: Although immunotherapy has emerged as a therapeutic strategy for many cancers, there are limited studies establishing the safety …
A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.
Uldrick TS, Gonçalves PH, Wyvill KM, Peer CJ, Bernstein W, Aleman K, Polizzotto MN, Venzon D, Steinberg SM, Marshall V, Whitby D, Little RF, Wright JJ, Rudek MA, Figg WD, Yarchoan R. Uldrick TS, et al. Oncologist. 2017 May;22(5):505-e49. doi: 10.1634/theoncologist.2016-0486. Epub 2017 Mar 24. Oncologist. 2017. PMID: 28341759 Free PMC article. Clinical Trial.
LESSONS LEARNED: Oral targeted agents are desirable for treatment of Kaposi sarcoma (KS); however, in patients with HIV, drug-drug interactions must be considered. ...Median CD4(+) count (HIV(+)) was 500 cells/L. Dose-limiting toxicities (DLTs) were grade …
LESSONS LEARNED: Oral targeted agents are desirable for treatment of Kaposi sarcoma (KS); however, in patients with HIV, drug- …
Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.
Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R. Uldrick TS, et al. J Clin Oncol. 2012 May 1;30(13):1476-83. doi: 10.1200/JCO.2011.39.6853. Epub 2012 Mar 19. J Clin Oncol. 2012. PMID: 22430271 Free PMC article. Clinical Trial.
PURPOSE: Alternatives to cytotoxic agents are desirable for patients with HIV-associated Kaposi's sarcoma (KS). Vascular endothelial growth factor-A (VEGF-A) contributes to KS pathogenesis. ...Four of five responders had received prior chemotherapy for KS. Over 202 …
PURPOSE: Alternatives to cytotoxic agents are desirable for patients with HIV-associated Kaposi's sarcoma (KS). Vascular endot …
Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with hemophilia.
Ragni MV, Belle SH, Jaffe RA, Duerstein SL, Bass DC, McMillan CW, Lovrien EW, Aledort LM, Kisker CT, Stabler SP, et al. Ragni MV, et al. Blood. 1993 Apr 1;81(7):1889-97. Blood. 1993. PMID: 8461474 Free article. Clinical Trial.
We studied the incidence and clinicopathologic features of NHL in 3,041 hemophiliacs followed at 18 US Hemophilia Centers between 1978 and 1989. ...Ten were stage IV, 1 stage II, and 3 stage IE. Ten (71.4%) were high-grade, 3 (21.4%) intermediate-gr …
We studied the incidence and clinicopathologic features of NHL in 3,041 hemophiliacs followed at 18 US Hemophilia Centers between 197 …
Continuous infusion etoposide in advanced AIDS-related kaposi sarcoma.
Remick SC, Reddy M, Ekman K, Vyzula R, Hilstro J, Horton J. Remick SC, et al. J Infus Chemother. 1996 Spring;6(2):92-6. J Infus Chemother. 1996. PMID: 8809657 Clinical Trial.
We conducted a preliminary phase II clinical trial to determine the toxicity, response, and survival rate of 72-hour continuous infusion etoposide administered to patients with AIDS-related Kaposi sarcoma. Nine patients with biopsy proven and measurable disease AIDS …
We conducted a preliminary phase II clinical trial to determine the toxicity, response, and survival rate of 72-hour continuous infusion eto …
Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium.
Brinker BT, Krown SE, Lee JY, Cesarman E, Chadburn A, Kaplan LD, Henry DH, Von Roenn JH. Brinker BT, et al. Cancer. 2008 Mar 1;112(5):1083-8. doi: 10.1002/cncr.23108. Cancer. 2008. PMID: 18224669 Free article. Clinical Trial.
BACKGROUND: Matrix metalloproteinases (MMPs) are overexpressed in Kaposi sarcoma (KS). The safety and efficacy of a novel, orally bioavailable MMP inhibitor, BMS-275291, was evaluated in patients with human immunodeficiency virus-associated KS and the correlation be …
BACKGROUND: Matrix metalloproteinases (MMPs) are overexpressed in Kaposi sarcoma (KS). The safety and efficacy of a novel, ora …
Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients.
Takebe N, Paredes J, Pino MC, Lownsbury WH, Agosti J, Krown SE. Takebe N, et al. J Interferon Cytokine Res. 1998 May;18(5):321-6. doi: 10.1089/jir.1998.18.321. J Interferon Cytokine Res. 1998. PMID: 9620359 Clinical Trial.
There were no deaths, no treatment-related grade 3/4 events, and no premature study discontinuations because of adverse events. ...Of 3 evaluable patients with Kaposi's sarcoma, 1 remained stable and 2 showed minimal progression. ...
There were no deaths, no treatment-related grade 3/4 events, and no premature study discontinuations because of adverse events …
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Lopez AM, et al. Cancer Chemother Pharmacol. 1999;44(4):303-6. doi: 10.1007/s002800050981. Cancer Chemother Pharmacol. 1999. PMID: 10447577
In a study of the treatment of refractory epithelial cell ovarian cancers with lipozomal doxorubicin utilizing intravenous doses of 50 mg/m(2) every 3 weeks, grade 3 PPES was observed in 29% of patients (10/35) and required dose reductions and/or dose …
In a study of the treatment of refractory epithelial cell ovarian cancers with lipozomal doxorubicin utilizing intravenous doses of 50 mg/m( …